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Abstract
Genomewide association studies have found significant genetic correlations among many neuropsychiatric disorders. In
contrast, we know much less about the degree to which structural brain alterations are similar among disorders and, if so, the
degree to which such similarities have a genetic etiology. From the Enhancing Neuroimaging Genetics through Meta-
Analysis (ENIGMA) consortium, we acquired standardized mean differences (SMDs) in regional brain volume and cortical
thickness between cases and controls. We had data on 41 brain regions for: attention-deficit/hyperactivity disorder (ADHD),
autism spectrum disorder (ASD), bipolar disorder (BD), epilepsy, major depressive disorder (MDD), obsessive compulsive
disorder (OCD), and schizophrenia (SCZ). These data had been derived from 24,360 patients and 37,425 controls. The
SMDs were significantly correlated between SCZ and BD, OCD, MDD, and ASD. MDD was positively correlated with BD
and OCD. BD was positively correlated with OCD and negatively correlated with ADHD. These pairwise correlations
among disorders were correlated with the corresponding pairwise correlations among disorders derived from genomewide
association studies (r= 0.494). Our results show substantial similarities in sMRI phenotypes among neuropsychiatric
disorders and suggest that these similarities are accounted for, in part, by corresponding similarities in common genetic
variant architectures.
Introduction
Neuropsychiatric disorders have substantial heritability, as
shown by many studies of twins and families [1]. Geno-
mewide association studies (GWAS) have shown that
common genetic variants account for some of this herit-
ability, and that some of this heritability is shared across
neuropsychiatric disorders [2–5]. The genetic overlap across
disorders may partly explain why these disorders tend to co-
occur with one another in both clinical and community
samples [6].
Subcortical brain volumes and cortical thickness/surface
area dynamically change from early development through
adulthood and old age. A study of the Enhancing Neuroi-
maging Genetics through Meta-Analysis (ENIGMA) Plasti-
city Working Group reported that changes in structural
magnetic resonance imaging (sMRI) phenotypes have herit-
abilities ranging from 5% for pallidum to 42% for cerebellar
gray matter [7]. Heritability estimates of change rates were
age-related and generally higher in adults than in children,
probably due to an increasing influence of genetic factors with
age [7]. However, it appears that later in adulthood heritability
decreases most likely due to cumulative effect of environ-
mental influences over the lifespan [8]. ENIGMA sMRI stu-
dies of different psychiatric and neurological disorders further
characterized MRI-derived phenotypes that can be used to
assess heritability (reviewed in [9]).
ENIGMA has also reported significant case vs. control
differences in sMRI phenotypes for: attention-deficit/
hyperactivity disorder (ADHD) [10, 11], autism spectrum
disorder (ASD) [12], bipolar disorder (BD) [13, 14],
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common epilepsy syndromes [15], major depressive dis-
order (MDD) [16, 17], obsessive compulsive disorder
(OCD) [18, 19], and schizophrenia (SCZ) [20, 21]. Here we
estimate the degree of similarity in sMRI phenotypes among
these disorders and evaluate whether these similarities are
influenced by corresponding similarities in common genetic
variant architectures.
Methods
Collection of structural neuroimaging summary
statistics
Summary statistics from ENIGMA structural neuroimaging
studies were collected from 12 multisite analyses published
by the ENIGMA Consortium for the following neu-
ropsychiatric disorders: ADHD [10, 11], ASD [12], BD
[13, 14], epilepsy [15], MDD [16, 17], OCD [18, 19], and
SCZ [20, 21]. Prior to computing the summary statistics, the
regional brain volumes had been segmented with a common
ENIGMA protocol using FreeSurfer software. Each site
performed these segmentations on their raw data. In addi-
tion, quality control protocols provided by ENIGMA were
run at each site. Details are at: http://enigma.ini.usc.edu/
protocols/imaging-protocols.
The ADHD and ASD samples comprised both youth and
adults. The other samples comprised adults only. The eth-
nicity of the patients was not available for all participants.
The “epilepsy” cohort comprised temporal lobe epilepsy,
genetic generalized epilepsy, and extra temporal epilepsy.
We analyzed 7 subcortical and 34 cortical regions (total of
41 brain regions; the mean of left and right structures) that
were included in the above specified ENIGMA studies. We
extracted the covariate-adjusted Cohen’s d standardized
mean differences (SMDs) denoting the case versus unaf-
fected comparison subject differences in subcortical volume
and cortical thickness/surface area measures. The covariates
used in these studies adjusted SMDs for several covariates
as indicated in Supplementary Table 1.
Collection of GWAS results among neuropsychiatric
disorders
Publicly available summary statistics from GWAS were
downloaded from the Psychiatric Genomics Consortium
(PCG) website (https://www.med.unc.edu/pgc/results-and-
downloads/) with the exception of GWAS results for MDD
coming from an online resource hosted by the University of
Edinburgh (https://doi.org/10.7488/ds/2458) and of GWAS
results for epilepsy coming from the online Epilepsy Genetic
Association Database (epiGAD) (http://www.epigad.org/
gwas_ilae2018_16loci.html). Presented in Supplementary
Table 2 are the numbers of affected cases and unaffected
control participants included in each GWAS. Note, the full
meta-analysis GWAS of MDD that included data from
23andMe was not available for public release, thus we used
the meta-analysis that combined results from the PGC
cohorts and UK Biobank.
Genetic and sMRI phenotype correlations among
neuropsychiatric disorders
Linkage disequilibrium (LD)-score regression, a popular
approach designed to analyze summary statistics from
GWAS, was used to quantify the amount of shared genetic
heritability, or genetic correlation (rg), existing between
pairs of neuropsychiatric disorders, considering HapMap3
LD-scores [22]. For these analyses, the largest and latest
GWAS available for each neuropsychiatric disorder was
selected and filtered to exclude markers with INFO < 0.90
or within the MHC region (hg19:chr6:25–35Mb) (Supple-
mentary Table 1). GWAS summary statistics were merged
with the HapMap3 reference panel (hg37 build), wherein
variants with a MAF ≥ 5% in the HapMap3 dataset were
retained, prior to computing (co)heritability estimates.
To derive an estimate of the degree to which sMRI
phenotypes were similar among disorders, we computed
pairwise Spearman’s rank correlation between the Cohen’s
d SMDs for each pair of disorders. We then used Pear-
son’s correlation to estimate, whether the genetic corre-
lations for each disorder covaried with the sMRI
phenotype correlations. We used a traditional permutation
framework to generate a null distribution of sMRI phe-
notype correlations by randomly shuffling Cohen’s d
values 10,000 times for each pair of disorders, then
recalculating sMRI correlations from the shuffled sets.
From the null distributions, we derived an empirical per-
mutation p value for each sMRI phenotype correlation.
However, a reliable p value could not be calculated due to
nonindependence between pairwise caused by sample
overlap between imaging studies. Adjustments for sample
overlap would be possible with individual-level data, but
the present study only had access to summary statistics. In
a leave-one-out analysis, we iteratively excluded one pair
of disorder correlations from the set and recalculated
Spearman’s correlation coefficients to determine whether
correlations were driven by any pair of disorders. Bino-
mial sign tests were used to determine whether the number
of disorders showing the same direction of effect in the
sMRI phenotypes was greater than expected by chance
(null probability of 50%). Per brain region, we performed
Cochran’s Q test implemented in the R package metafor
(v.2.1–0) to determine whether variability among Cohen’s
d values was greater than expected by chance. All statis-
tical analyses were performed with R version 3.5.2
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(R Core Team, 2018). We adjusted for repeated correla-
tion tests using the Bonferroni procedure. Correlations
showing a Bonferroni-adjusted p < 0.05 were considered
significant (threshold p= 0.00227).
Results
Sample demographics for the twelve studies by the
ENIGMA Consortium on structural brain abnormalities in
neuropsychiatric disorders are presented in Table 1.
Case–control differences in subcortical volume and
cortical surface area and thickness within
neuropsychiatric disorders
Figure 1 presents an anatomical graph of the standardized
effect sizes (Cohen’s d) measuring alterations in subcortical
volume, cortical surface area and cortical thickness for 41
brain regions within seven neuropsychiatric disorders—
ADHD, ASD, OCD, epilepsy, MDD, BD, and SCZ. These
have been reported on prior publications. The variation in
color from blue to red illustrates the phenomenon of SBRV,
with some regions showing significant reductions (blue) in
volume/thickness/surface areas and others not being
affected. As indicated by the blueness of the cells, the most
prominent reductions were seen for SCZ (mean Cohen’s d
across all regions=−0.22, SE= 0.014), epilepsy (mean
Cohen’s d=−0.12, SE= 0.017) and BD (mean Cohen’s
d=−0.097, SE= 0.011). The smallest changes were
observed for MDD (mean Cohen’s d=−0.018, SE=
0.006). All regions except for the caudate and putamen
exhibited significant differences in the magnitude of
Cohen’s d across disorders (Cochran’s Q p values=
0.012–2.8 × 10−32). Eighteen sMRI phenotypes exhibited
homogeneity with respect to sign of Cohen’s d across each
of the neuropsychiatric disorders evaluated (binomial sign
test p values < 0.05): cortical thicknesses for caudal middle
frontal gyrus, entorhinal cortex, fusiform gyrus, inferior
temporal gyrus, insula, lateral orbitofrontal cortex, lingual
gyrus, middle temporal gyrus, paracentral lobule, para-
hippocampal gyrus, pars opercularis of inferior temporal
gyrus, precentral gyrus, precuneus, rostral anterior cingulate
cortex, and supramarginal gyrus; subcortical volume for the
hippocampus; and surface area for middle temporal gyrus,
pars triangularis of inferior temporal gyrus, and pericalcar-
ine cortex. For sMRI phenotypes for 39 regions of interest
varying degrees of heterogeneity were noted in terms of
discrepancy of signs of Cohen’s d. For example, individuals
with ASD showed a slightly thicker cortex in the rostral
Table 1 Sample demographics for the twelve studies by the ENIGMA Consortium into structural brain alterations in neuropsychiatric disorders.
Disorder MRI measure Cases (n) Controls (n) Total n Sites Weighted mean age (cases) Weighted mean age (controls) References
ADHD Cortical thickness 2246 1934 4180 36 19.2 18.1 [2, 28]
Surface area 2246 1934 4180 36 19.2 18.1
Subcortical volume 1713 1529 3242 23 18.6
ASD Cortical thickness 1571 1651 3222 49 15.4 [18]
Surface area
Subcortical volume
BD Cortical thickness 1837 2582 4419 28 38.4a 35.6a [19, 30]
Surface area 1820 2582 4402 28 38.4a 35.6a
Subcortical volume 1710 2594 4304 20 40.1a 36.5a
Epilepsy Cortical thickness 2149 1727 3876 24 34.4 33.3 [7]
Surface area
Subcortical volume
MDD Cortical thickness 1911 7663 9574 20 44.8a 54.6a [6, 22]
Surface area 1902 7658 9560 20 44.8a 54.6a
Subcortical volume 1728 7199 8927 15 43.3a 56a
OCD Cortical thickness 1498 1435 2933 27 32.1 30.5 [26, 41]
Surface area 1497 1433 2930 27 32.1 30.5
Subcortical volume 1495 1472 2967 25 32.0 30.6
SCZ Cortical thickness 4474 5098 9572 39 32.3a 34.5a [27, 34]
Surface area 4434 5073 9507 39 32.3a 34.5a
Subcortical volume 2028 2540 4568 15 34.0a 31.0a
aWeighted mean not provided in paper; computed from descriptive statistics.
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middle frontal gyrus, individuals with ADHD showed no
difference, and all other disorders showed a thinner cortex
in this region compared to controls.
sMRI phenotype correlations among
neuropsychiatric disorders
For each pair of disorders, we computed the Pearson corre-
lation between their sMRI phenotypes listed in Fig. 1. These
are listed in Table 2 (and visualized in Fig. 2), sorted by the
magnitude of the correlation. The p values reported in Table 2
are potentially downwardly biased due to inability to properly
adjust for spatial coherence of nearby brain regions. Tradi-
tional permutation p values are provided as a column in
Table 2, which attempts to correct for potential biases due to
spatial coherence. However, we were restricted from using a
spatial permutation framework to generate a null distribution
of correlations, because we are jointly analyzing two cortical
maps (cortical thickness and surface area) that are fully
overlapped. The highest positive correlation was between
SCZ and BD (r= 0.81, df= 73, p < 1.3 × 10−18, Bonferroni
p= 2.38 × 10−17). There were a few additional nominally
significant negative correlations, which did not survive mul-
tiple testing correction: MDD and epilepsy (r=−0.37, p=
0.02), MDD and ADHD (r=−0.33, p= 0.004), SCZ and
ADHD (r=−0.32, p= 0.005), ADHD and epilepsy (r=
−0.36, p= 0.02), and a positive correlation between MDD
and ASD (r= 0.26, p= 0.02).
Correlation of shared genetic heritability with brain
structural correlation
Figure 3 shows the pairwise correlations of sMRI pheno-
types and genetic overlap across each pair of neu-
ropsychiatric disorders. The LD-score cross-disorder
genetic correlations are positively correlated with the sMRI
phenotype cross-disorder correlations (Spearman’s ρ=
0.44, p= 0.049). Leave-one-out sensitivity analyses con-
firmed that the direction of the correlation was positive and
remained moderate in magnitude despite removal of indi-
vidual pairs of disorders from the correlation test (range of
Spearman’s ρ= 0.35–0.58), except for removing SCZ/BD
(Spearman’s ρ= 0.35). SCZ and BD showed the highest
degree of concordance with respect to genetic and sMRI
phenotype correlations.
Discussion
Our analysis of summary statistics from the ENIGMA
ADHD, ASD, BD, MDD, OCD, SCZ, and epilepsy
Working Groups and the predominantly PGC
case–control GWAS identified two novel findings. First,
we found substantial correlations for some disorders in the
pattern of sMRI case–control differences across sub-
cortical and cortical regions in line with recently pub-
lished study of [23]. Second, these cross-disorder
Fig. 1 A brain imaging plot showing standardized mean differ-
ences (Cohen’s d) measuring case–control differences in sub-
cortical volumes and cortical thickness for seven neuropsychiatric
disorders. Results were obtained from ENIGMA working group
publications. Negative values for Cohen’s d indicate smaller sizes of
brain regions in cases versus unaffected comparisons. Note: ADHD
attention-deficit/hyperactivity disorder, ASD autism spectrum dis-
order, BD bipolar disorder, MDD major depressive disorder, OCD
obsessive compulsive disorder, SCZ schizophrenia.
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correlations in SBRV could partly be explained by the
genetic correlations reported for these disorders from
GWAS [3].
The cross-disorder correlations in SBRV are intriguing
because, like cross-disorder genetic correlations, they sug-
gest that these disorders, to varying degrees, share aspects
Fig. 2 A heatmap of the cross-disorder pairwise sMRI correlations
between seven neuropsychiatric disorders examined in this study.
Colors in the plot correspond to the magnitude of the Pearson’s r
coefficients, which are provided in each tile. Note: ADHD attention-
deficit/hyperactivity disorder, ASD autism spectrum disorder, BD
bipolar disorder, MDD major depressive disorder, OCD obsessive
compulsive disorder, SCZ schizophrenia.
Fig. 3 Scatter plot showing the correlation of correlations. Genetic
correlations (rg) computed by LD-score regression are on the hor-
izontal axis (with standard error bars), with correlations of Cohen’s d
values displayed on the vertical axis. Each dot is color-coded
according to the pairwise disorder correlations that were computed.
The dotted line represents the best-fit regression line. The Spearman’s
rho (ρ) and p value are provided at the top-left corner of the panel.
Note: ADHD attention-deficit/hyperactivity disorder, ASD autism
spectrum disorder, BD bipolar disorder, MDD major depressive dis-




smallest to largest p value) based
on Cohen’s d values obtained
from the ENIGMA Project.
Disorder 1 Disorder 2 sMRI correlation
Pearson’s r




BD SCZ 0.81 73 0.068 1.13E−18 2.38E−17 <1E10−4
BD MDD 0.69 73 0.085 1.21E−11 2.55E−10 <1E10−4
OCD SCZ 0.65 72 0.09 5.53E−10 1.16E−08 <1E10−4
MDD SCZ 0.58 73 0.095 5.55E−08 1.17E−06 <1E10−4
ADHD BD −0.53 73 0.099 1.18E−06 2.48E−05 <1E10−4
BD OCD 0.5 72 0.102 4.74E−06 9.95E−05 <1E10−4
MDD OCD 0.46 72 0.104 3.28E−05 6.89E−04 <1E10−4
ASD BD 0.38 73 0.108 8.98E−04 0.02 <1E10−4
ASD SCZ 0.36 73 0.109 1.35E−03 0.03 0.0176
ADHD MDD −0.33 73 0.111 4.27E−03 0.09 0.019
ADHD SCZ −0.32 73 0.111 4.63E−03 0.1 0.0014
Epilepsy MDD −0.37 39 0.149 0.02 0.38 0.0056
ADHD Epilepsy −0.36 39 0.149 0.02 0.41 0.004
ASD MDD 0.26 73 0.113 0.02 0.46 0.024
Epilepsy OCD −0.19 39 0.157 0.23 1 0.22
BD Epilepsy 0.17 39 0.158 0.3 1 0.3
ADHD OCD −0.1 72 0.117 0.39 1 0.39
ADHD ASD −0.06 73 0.117 0.6 1 0.6
Epilepsy SCZ −0.03 39 0.16 0.86 1 0.85
ASD Epilepsy 0.02 39 0.16 0.91 1 0.91
ASD OCD 0 72 0.118 0.97 1 0.97
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of their etiology and pathophysiology. Any interpretation of
the cross-disorder sMRI correlations must keep in mind
that, for all disorders, the case–control differences in sMRI
measures are small (Fig. 1). The largest Cohen’s d values
are only −0.5 for SCZ [20, 21], −0.4 for epilepsy [15],
−0.3 for BD [13, 14], −0.2 for ADHD [10, 11] and ASDs
[12], and −0.1 for MDD [16, 17] and OCD [18, 19]. These
small case–control differences are consistent with results
from GWAS and environmental risk studies, which speaks
to the fact that the effects of common risk factors are, with
some rare exceptions, individually small. Although it is
conceivable that these small risks could accumulate to
create a more dramatic pathophysiology in the brain, the
ENIGMA data show that this is not the case for sMRI
measures. Consistent with this finding, interindividual dif-
ferences in neuroimaging account for only a small amount
of the variance in symptom expression or behavioral mea-
sures of symptomatic or behavioral variance [24].
The most prominent case–control differences in cortical
thickness/surface area and subcortical volumes were
observed for SCZ [20, 21] and BD [13, 14]. These disorders
also had the highest sMRI phenotype correlations and both
also showed strong sMRI phenotype correlations with
MDD [16, 17] and OCD [18, 19]. As Fig. 2 shows, these
disorders clustered together in the three-dimensional con-
figuration required to capture cross-disorder sMRI pheno-
type similarity. The high sMRI correlation between SCZ
and BD is consistent with prior reports of sMRI similarities
between the two disorders [25]. Moreover, a large body of
literature reports substantial etiologic overlap between the
two disorders [26–30]. Because of such data, the SCZ and
BD have been described as sharing a continuum of etiology
leading to psychotic [31], neurophysiological [31] and
neurocognitive [32] symptoms. The ENPACT study [33]
showed shared fronto–temporo–occipital gray matter
volume deficits in the right hemisphere of two disorders. A
systematic review of associations between functional MRI
activity and polygenic risk for SCZ and BD [26] reported
that genetic load for these disorders affects task-related
recruitment of predominantly frontal lobe brain regions.
Many studies have reported that OCD can be a comorbid
diagnosis with SCZ or that patients with SCZ can have OCD
symptoms [34–41]. Presented findings of a significant over-
lap in sMRI phenotypes along with the known SCZ/OCD
genetic correlations suggests that more work should examine
shared pathophysiologic features between these disorders and
should assess the degree to which confounds, such as med-
ication status or chronicity, might explain these results.
The sMRI phenotype correlations mirror, to some extent,
the cross-disorder correlations from GWAS. Figure 3 shows
a modest, yet distinct, linear correlation between the sMRI
phenotype and genetic correlations. In the upper right-hand
section of the plot, we see disorders having high genetic and
high sMRI correlations. These are SCZ/BD, SZ/MDD, BD/
MDD, OCD/BD, and OCD/MDD. The inclusion of MDD
in this group is notable given that it is part of the bipolar
diagnosis and often occurs comorbid with other disorders.
MDD also has a high genetic correlation with ADHD but a
negative sMRI correlation, which makes that pair an outlier
in Fig. 3.
In the lower left region of Fig. 3, we see disorders with
low genetic and low sMRI correlations. These involve
correlations of epilepsy, and correlations of ADHD with all
disorders except ASDs and MDD, although the latter is
somewhat of an outlier. ASDs tend to have both modest
genetic correlations and modest sMRI correlations with
most other disorders and, hence, populates the middle range
of the figure. Like the sMRI correlations among disorders,
all genetic correlations with epilepsy are low, which is
consistent with the low genetic correlation between neuro-
logical and psychiatric disorders as reported by [2].
The finding that SBRV correlations are correlated with
genetic correlations suggests that future studies of SBRV
should consider genetic sources of etiology. Yet, because
only about 24% of the variance in the SBRV correlations can
be accounted for by the genetic correlations, environmental
sources of etiology and disease-specific genetic contributions
must also be considered. These include shared confounders,
such as chronicity and medication exposure, along with
shared etiologic events such as birth complications or expo-
sure to toxins in utero. Our prior studies of SBRV in ADHD
implicated the regulation of genes in apoptosis, autophagy
and neurodevelopment pathways in ADHD [42, 43]. Neu-
rodevelopmental pathways had also been implicated in the
cross-disorder analysis of the PCG [3], which suggests that
cross-disorder similarities in these pathways may account for
cross-disorder similarities in SBRV.
Although we used data derived from very large samples
(ENIGMA, iPSYCH, and the PGC), several limitations
moderate the strength of our conclusions. We inherit all the
limitations of the constituent studies, but are further limited
because we analyzed summary statistics, not the original
data, which would require the sharing of individual subject
level data, an ongoing effort among the ENIGMA disorder
working groups. Thus, we cannot determine whether the
possible use of controls shared among studies affected our
results. It is also possible that some research participants
were included in the genetic and sMRI data sets for the
same disorder. The p value obtained by our Spearman’s
correlation test of cross-disorder sMRI and genetic corre-
lations may be inaccurate due to spatial autocorrelation
among sMRI Cohen’s d estimates, which can downwardly
bias standard errors and lead to deflated p values. Con-
sidering we are not able to completely address with auto-
correlation among brain regions using summary statistics
alone, the p value from our primary analysis (presented in
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Fig. 3) should be interpreted with caution. Another problem
is that we could not address effects of medications or
chronicity on brain structure. Furthermore, for some of the
disorders, we could use youth and adult data, whereas for
others only adult effect data were used. Because findings
can differ substantially depending on the age range of the
samples included (e.g., [10, 11, 18, 19], this might have
influenced our findings. For these reasons, analyses of
participant level data will be needed to address these issues
to draw stronger and more detailed conclusions. We also
did not have any longitudinal data available, which limits
the ability to test hypotheses about shared and unique
developmental trajectories among disorders.
Despite these limitations, we have documented cross-
disorder correlations in SBRV as assessed by sMRI. These
cross-disorder SBRV correlations are positively associated
with the disorders’ corresponding cross-disorder genetic
correlations. This finding is a novel contribution worthy of
further study that contributes to novel body of literature
focused on cross-level correspondence of genetic and neu-
roimaging presentations of different psychiatric disorders
[44–49]. Our work supports conclusions from previous
GWAS studies suggesting a partially shared etiology and
pathophysiology among many disorders [2, 50]. Disorders
like SCZ and BD or ADHD and ASD, which are distinct in
the diagnostic nomenclature, show significant overlap in
etiology and pathophysiology. Further studies are needed to
discern why brain regions are selectively affected by the
risk factors that cause sMRI abnormalities [42, 43] and why
these effects are correlated across disorders. Such studies
may give insights into new treatment targets.
Data availability
URLs for GWAS SCZ from ckqny.scz2snpres.gz
(https://www.med.unc.edu/pgc/results-and-downloads), ASD
from iPSYCH-PGC_ASD_Nov2017.gz (https://www.med.
unc.edu/pgc/results-and-downloads), OCD from PGC_OC-
D_Aug2017-20171122T182645Z-001.zip > ocd_aug2017.gz
(https://www.med.unc.edu/pgc/results-and-downloads),
ADHD from adhd_ul2017.gz (https://www.med.unc.edu/pgc/
results-and-downloads), BD from daner_PGC_BIP32b_md-
s7a_0416a.gz (https://www.med.unc.edu/pgc/results-and-dow
nloads), Epilepsy from all_epilepsy_METAL.gz (http://www.




Custom R scripts used to generate results in this study can
be made available upon request.
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